NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday proposed to cover the anti-PD-1 drug nivolumab (Bristol Myers Squibb's Opdivo) as a second-line option for patients with certain kinds of non-small cell lung cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.